Biotech stocks are gaining traction as the market shifts focus towards recovery from the pandemic, with significant attention on companies like AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE). AbbVie, bolstered by its acquisition of Allergan, continues to rely heavily on its top drug, Humira, which accounts for nearly half of its profits. Meanwhile, Pfizer remains a key player in vaccine development and has a diverse pipeline that includes treatments for various diseases, enhancing its market position.

The biotech sector’s growth potential is underscored by the ongoing demand for innovative therapies, particularly in oncology and immunology. As companies navigate the complexities of drug development and FDA approvals, the potential for substantial stock price appreciation remains high, especially for firms addressing prevalent health issues. Investors are advised to keep an eye on companies with promising pipelines and strong market relevance, as these factors can significantly influence stock performance.

For market professionals, the takeaway is clear: now may be an opportune time to consider biotech investments, particularly those under $20, as the sector continues to evolve and adapt in response to global health challenges.

Source: benzinga.com